ArticleJournal of Korean medical science2007
Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis.
Article in Journal of Korean medical science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.Respiratory research · 2018Pooled it
- Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.BMC cancer · 2016Pooled it
- Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies.BMC cancer · 2015Pooled it
- Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.Molecular biology reports · 2013Pooled it
- Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis.PloS one · 2012Pooled it
- Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation.Cancer immunology, immunotherapy : CII · 2025Article
- Review
- Article
- Effects of RNAi-induced Skp2 inhibition on cell cycle, apoptosis and proliferation of endometrial carcinoma cells.Experimental and therapeutic medicine · 2019Article
- Classification of malignant and benign tumors of the lung by infrared spectral histopathology (SHP).Laboratory investigation; a journal of technical methods and pathology · 2015Article
- Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review.OncoTargets and therapy · 2015Article
- Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer.Biomedical reports · 2014Article
- Immunohistochemical Expression of DCUN1D1 in Non-small Cell Lung Carcinoma: Its Relation to Brain Metastasis.Cancer research and treatment · 2012Article
- Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.Cancer · 2011Review
- Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.Pathology oncology research : POR · 2010Article
- Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.The American journal of pathology · 2010Article
- Ber-EP4, CK1, CK7 and CK14 are useful markers for basaloid squamous carcinoma: a study of 45 cases.Head and neck pathology · 2008Article
- [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)].Wiener medizinische Wochenschrift (1946) · 2007Review
- New P16 Expression Criteria Predict Lymph Node Metastasis in Patients With Non-small Cell Lung Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancers (NSCLC) vary in their biologic behavior. Recurrence and tumor-related mortality may be attributable to molecular abnormalities in primary tumors. This study evaluated such immunophenotypes with regard to cell cycle regulation and proliferation, apoptosis, and angiogenesis, to determine their significance for patient outcome. Core biopsies from 219 patients with NSCLC were assembled on tissue microarrays, and the expressions of p16, p21, p27, cyclin B1, cyclin E, Ki-67, caspase-3, survivin, bcl-2, VEGF, and endostatin were evaluated by immunohistochemistry. Despite previously described prognostic relevance of some of the investigated molecules, many of those markers were not directly associated with recurrence or survival. However, there was a trend for p16 immunoreactivity to be associated with a good prognosis (57% vs. 42% in 5-yr survival) (p=0.071). bcl-2 expression was strongly correlated with a better outcome (65% vs. 45% in 5-yr survival) (p=0.029), and the hazard of death for bcl-2 positive patients was 0.42 times of that for bcl-2 negative patients (p=0.047). A multivariate analysis with Cox proportional hazards model confirmed that the lymph node status (p=0.043) and stage (p=0.003) were other independent prognostic factors. Our results suggest that p16 and bcl-2 provide prognostic information independent of the TNM stage in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.